COVID-19 and per capita green tea consumption: update

Maksim Storozhuk

DOI: https://doi.org/10.1101/2022.06.06.22276060

2022-06-08

MedRxiv

Abstract:Purpose: In spite of the development of numerous vaccines for the prevention of COVID-19 and approvement of several drugs for its treatment, there is still a great need in effective and inexpensive therapy of this disease. Pharmacological evidence suggesting the therapeutic potential of green tea catechins in amelioration/treatment of COVID19 is growing rapidly, however, there are only a few epidemiological studies addressing this possibility. The aim of this study was to provide update regarding ecological study assessing this issue as of January 2021. Methods: The methodological approach used in this report is similar to that described previously. Briefly, information about COVID-19 morbidity (defined as a total number of cases per million population) and mortality (defined as a total number of deaths per million population) for a specific date was directly obtained from Worldometers info. Coronavirus. Analysis was restricted to 134 countries or territories with at least 3 million population. Twenty-one of these countries/territories, with estimated per/capita green tea consumption above 150 g (annually), were considered as a group with the high consumption. Countries/territories with the estimated per/capita green tea consumption below 150 g (N=82) were considered as the group with low the consumption. Results: Pronounced differences in COVID-19 morbidity and mortality between groups of countries with high and low green tea consumption were found as of February 20, 2022. These differences were still observed in a subset of countries with HDI above 0.55. Moreover, in this restricted subset of countries, weak but statistically significant correlations between COVID-19 morbidity (or mortality) and per/capita green tea consumption were observed in a multiple regression model accounting for: population density, percentage of population aged above 65, and percentage of urban population. Conclusion: The obtained results provide additional, though indirect, support of the idea that green tea catechins can be useful for treatment/amelioration of COVID-19. These results are in line with emerging evidence from other studies, including pharmacological. Nevertheless, further research is necessary to directly validate or reject this idea.